Clinical Audit of Anticoagulant Therapy with Pregnancy in Al-Emarati Hospital
Date
2022-05-11
Authors
Mustafa Abu Jayyab
Mosheer Al-Dhdouh
Khamis Elessi
Journal Title
Journal ISSN
Volume Title
Publisher
Al-Quds University, Deanship of Scientific Research
Abstract
Background: Thromboembolic disorders can be considered a fatal problem in pregnancy. Anticoagulant therapy plays an important role in both treatment and prevention. Warfarin is the best drug to use but carries the risk of bleeding in mothers and fetuses, especially in the late pregnancy and delivery. Moreover, the risks of embryopathy from warfarin in early pregnancy cannot be excluded. Parenteral heparin has the advantage of the inability to cross the placental barrier but still can be a cause of bleeding problems in pregnancy, and its long-term use still carries the problems of maternal bone demineralization (Bates, Greer et al. 2012).